Targeting lipogenesis promotes the synergistic effect of the selective HDAC6 inhibitor ITF3756 with bortezomib in colon cancer cells
Marzia Franzò, Chiara Zichittella, Diana Di Liberto, Giovanni Pratelli, Federica Affranchi, Antonietta Notaro, Michela Giuliano, Sonia Emanuele · 2025
Read Targeting lipogenesis promotes the synergistic effect of the selective HDAC6 inhibitor ITF3756 with bortezomib in colon cancer cells by Marzia Franzò, Chiara Zichittella, Diana Di Liberto, Giovanni Pratelli, Federica Affranchi, Antonietta Notaro, Michela Giuliano, Sonia Emanuele (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12742218.txt.
Description
Marzia Franzò and co-authors test a drug pairing against colon cancer cells, in a 2025 paper. One drug blocks a single member of a protein editing family that also helps control fat making in cells. That member is tied to colon cancer growth and poor outlook, which makes it a target of interest.
The blocker alone cut cell survival and raised fat making in two colon cancer lines. The second drug, a proteasome blocker, also pushes fat build up. At low, sub toxic doses the pair killed far more cells together than apart. The effect ran through fat control switches in the cell. Blocking fat making may thus sharpen this pairing.
Catalog record
| CREATOR | Marzia Franzò, Chiara Zichittella, Diana Di Liberto, Giovanni Pratelli, Federica Affranchi, Antonietta Notaro, Michela Giuliano, Sonia Emanuele |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 48 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |